Billing and Coding MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer (A58681) Final Billing and Coding Article - Effective August 08, 2022

This Local Coverage Determination (LCD) has completed the Open Public Meeting and is now finalized under contractor numbers: 02102 (AK), 02202 (ID), 02302 (OR), 02402 (WA), 03102 (AZ), 03202 (MT), 03302 (ND), 03402 (SD), 03502 (UT), and 03602 (WY). 

Medicare Coverage Database (MCD) Number/Contractor Determination Number: A58681

LCD Title: Billing and Coding MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer

Effective Date: August 08, 2022

Summary of LCD: The information in this article contains billing, coding or other guidelines that complement the Local Coverage Determination (LCD) for MolDX: Lab-Developed Tests for Inherited Cancer Syndromes in Patients with Cancer L38974

Visit the Proposed LCDs webpage to access this Billing and Coding Article.

 

Last Updated Jun 22 , 2022